Does Metformin Affect Your Eyesight? A Closer Look

Metformin does affect your eyesight, and the bulk of current evidence points toward protection rather than harm. Across studies involving hundreds of thousands of patients, this widely prescribed diabetes drug has been linked to lower rates of diabetic retinopathy, age-related macular degeneration, glaucoma, and retinal vein occlusion. The story is not entirely straightforward, though. Dose matters in unexpected ways, newer diabetes medications may outperform metformin on some eye outcomes, and there is one indirect route through which long-term metformin use could quietly damage vision.

Diabetic Retinopathy

Diabetic retinopathy is the eye condition most closely tied to metformin’s everyday use, since the drug is a first-line treatment for type 2 diabetes and high blood sugar is the primary driver of retinal damage in diabetes. But the emerging research suggests metformin does more than just lower blood sugar. In a population-based cohort study of over 10,000 people with type 2 diabetes, metformin use was linked to about a 24% lower risk of developing nonproliferative diabetic retinopathy and a substantially lower risk of sight-threatening retinopathy compared with non-users, even after accounting for blood sugar control.¹ Multiple clinical and preclinical studies have pointed in the same direction.²

One reason researchers believe the benefit goes beyond glucose control is what happens inside the eye itself. In a study that measured inflammatory proteins in the vitreous fluid of diabetic patients, those taking metformin had dramatically lower levels of key inflammatory signals compared to diabetic patients not on metformin. For example, VEGF, a protein that drives abnormal blood vessel growth in the retina, was elevated about 16-fold in metformin users versus nearly 44-fold in non-users (both compared to non-diabetic controls).³ That difference is large enough to matter clinically, because runaway VEGF production is a hallmark of the progression from mild to vision-threatening retinopathy.

When compared with other diabetes medications, metformin holds up reasonably well. In an analysis of over 60,000 eyes, progression from mild nonproliferative diabetic retinopathy to worse stages within one year was about 7% among metformin users and 10% among people using no glucose-lowering medication. SGLT-2 inhibitors and DPP-4 inhibitors showed similar or slightly lower progression rates, but the differences between drug classes were modest.⁴

Age-Related Macular Degeneration

The connection between metformin and age-related macular degeneration is arguably the most intriguing finding in this area, because AMD is not a diabetes complication. It is the leading cause of vision loss in older adults regardless of their blood sugar. Yet multiple large studies now suggest that people who take metformin develop AMD less often than people who do not.

A case-control study using insurance claims data found that metformin use was associated with about a 6% lower odds of developing AMD overall, and the benefit was dose-dependent: low to moderate doses over two years showed the clearest reduction, while the highest doses did not show a significant effect.⁵ A subsequent study looked specifically at people without diabetes and still found a protective association, with roughly 17% lower odds of developing any AMD and 15% lower odds of dry AMD among metformin users.⁶ The fact that this showed up even in non-diabetics strengthens the case that metformin’s eye effects are not just a side benefit of better glucose control.

There is a catch, however. The dose-response curve is not a straight line downward. A population-based study of type 2 diabetes patients found that people on very high doses of metformin (more than 25 defined daily doses per month) actually had a higher risk of AMD than those taking moderate amounts.⁷ This inverted-U pattern, where moderate doses help and very high doses may not, has appeared in more than one study and remains a puzzle. It could reflect something real about how the drug’s cellular effects change at higher concentrations, or it could be a statistical artifact of sicker patients requiring higher doses. Either way, it is a signal worth watching.

Glaucoma

Glaucoma destroys the retinal ganglion cells that carry visual information from the eye to the brain, and it is the leading cause of irreversible blindness worldwide. The evidence linking metformin to lower glaucoma risk is building on multiple fronts: population data, genetic analyses, and animal experiments.

A prospective cohort study combined with a meta-analysis of existing research found that metformin use was associated with a 19% lower risk of glaucoma among people of European ancestry, independent of blood sugar control, eye pressure, and how long someone had diabetes. The meta-analysis confirmed a consistent pooled effect across cohort studies.⁸ The same study used a genetic approach called Mendelian randomization and found that mimicking metformin’s biological targets genetically was associated with about a 34% lower glaucoma risk, adding causal plausibility to the association.

Data from the NIH All of Us research program showed an even stronger link: after adjusting for other factors, metformin users had roughly two-thirds lower odds of developing primary open-angle glaucoma compared to non-users. Strikingly, the use of other diabetes medications was associated with an increased odds of glaucoma, making metformin look protective by comparison rather than diabetes treatment in general being helpful.⁹

In animal models, the story is consistent. Metformin given to mice with retinal ischemia significantly prevented the loss of retinal ganglion cells and preserved retinal structure.¹⁰ Other lab studies have shown that metformin improves the survival and function of retinal ganglion cells after injury by promoting healthy mitochondrial turnover.¹¹ The protective mechanism appears to involve keeping mitochondria fused and functional rather than fragmented, which reduces the oxidative stress that kills ganglion cells.¹²

How Metformin Reaches the Eye

One question that puzzled researchers early on is whether an oral diabetes pill could even get to the retina in meaningful amounts. The retina is protected by a blood-retina barrier, similar to the blood-brain barrier, that blocks many drugs from crossing. But animal studies have confirmed that metformin given systemically does activate its key cellular pathway (AMPK) in retinal tissue, meaning enough drug gets through to have a biological effect.¹³

Once in the retina, metformin influences a range of processes through that AMPK pathway. It dials down inflammation, reduces oxidative stress, promotes healthy recycling of damaged cell components (autophagy), and restrains the growth of abnormal blood vessels.¹⁴ In lab settings, metformin has protected both photoreceptors (the cells that detect light) and the retinal pigment epithelium (the support layer behind them) from acute injury and has slowed inherited retinal degeneration.¹⁵ It has also protected retinal pigment cells from damage caused by oxidative stress¹⁶ and from a toxic byproduct of sugar metabolism called methylglyoxal, which accumulates in diabetes and damages cells throughout the body.¹⁷

Retinal Vein Occlusion

Retinal vein occlusion, sometimes called a “stroke of the eye,” occurs when a vein draining blood from the retina becomes blocked, causing sudden vision loss. It is more common in people with diabetes, high blood pressure, and other cardiovascular risk factors. A nationwide population study in diabetic patients found that metformin use was a significant protective factor against retinal vein occlusion.¹⁸ A systematic review and meta-analysis went further, estimating that metformin monotherapy roughly halved the risk of retinal vein occlusion, though the authors cautioned that this finding came from single large cohorts rather than randomized trials and needs to be confirmed independently.¹⁹

The Vitamin B12 Blind Spot

If metformin mostly looks good for the eyes, why should you be cautious? Because there is one well-documented indirect risk. Metformin is known to reduce the body’s absorption of vitamin B12, and over months or years of use, this can lead to genuine B12 deficiency. Optic neuropathy, damage to the nerve that connects the eye to the brain, is a recognized complication of B12 deficiency.²⁰ Symptoms include blurring or dimming of vision, particularly for colors, that can be mistaken for age-related changes or even early macular degeneration.

The irony is that while metformin may reduce the risk of several major eye diseases, ignoring a slowly depleting B12 level could quietly erode the optic nerve. The fix is straightforward: if you take metformin long-term, periodic B12 monitoring and supplementation when needed prevent this entirely. Most diabetes care guidelines already recommend this, but it is not always followed in practice.

Cataracts

Given the promising results for retinal and optic nerve conditions, you might expect cataracts to follow the same pattern. The evidence here is thinner and more mixed. One study found that metformin reduced inflammatory proteins in the fluid inside the eye of cataract patients with type 2 diabetes, suggesting it might slow cataract development.²¹ But a population-based study from the Rotterdam Study found no association between any diabetes medication, metformin included, and the risk of developing cataracts.²² For now, there is no strong reason to believe metformin meaningfully helps or hurts cataract risk.

Corneal Nerves and Dry Eye

The cornea, the clear front surface of the eye, is one of the most densely nerve-supplied tissues in the body. Diabetes gradually damages those tiny corneal nerves, contributing to dry eye, poor healing after injury, and reduced corneal sensitivity. A recent study using corneal confocal microscopy found that people with type 2 diabetes who were on metformin had higher corneal nerve fiber density and length compared to diabetic patients not on metformin. The metformin group also showed lower levels of immune cell activity in the corneal nerve layer.²³ This is compelling because corneal nerve damage often tracks with nerve damage elsewhere in the body, so metformin’s corneal benefit may reflect a broader neuroprotective effect.

On the other side of the ocular surface story, a lab study looked at the effect of metformin on the meibomian glands, the tiny oil-producing glands in the eyelids that prevent tears from evaporating. Metformin boosted lipid production and cell differentiation at lower concentrations, but at higher concentrations, cells showed signs of stress and damage, including membrane rupture after prolonged exposure.²⁴ This was a cell-culture study, so the concentrations used do not translate directly to what happens in a person taking a pill. But it does hint that the drug’s effects on the ocular surface are not uniformly positive at every dose.

How Metformin Stacks Up Against Newer Diabetes Drugs

Metformin has been around since the 1950s. Newer classes of diabetes drugs, particularly GLP-1 receptor agonists (like semaglutide) and SGLT-2 inhibitors (like empagliflozin), have attracted attention for their own potential eye benefits. The head-to-head comparisons are starting to come in, and they are worth paying attention to if you take one of these medications.

For glaucoma, patients on GLP-1 receptor agonists had about 40-50% lower risk of developing open-angle glaucoma compared to metformin users at one, two, and three years of follow-up.²⁵ A multinational cohort study similarly found that SGLT-2 inhibitor users had about 36% lower risk of open-angle glaucoma and 27% lower risk of ocular hypertension compared to metformin users over five years.²⁶

These comparisons do not mean metformin is bad for glaucoma. As discussed above, metformin itself appears protective relative to no treatment or to other older diabetes medications. But if you are already on a GLP-1 agonist or SGLT-2 inhibitor for diabetes or weight management, you may be getting even more eye protection than metformin alone would provide. For diabetic retinopathy progression, the differences between drug classes were smaller and less consistent, with metformin performing similarly to most alternatives.⁴

Metformin Eye Drops

One frontier in this research is whether metformin could be delivered directly to the eye rather than taken as a pill. The appeal is obvious: higher local concentrations in the eye tissue that needs protection, without the systemic side effects like gastrointestinal upset or B12 depletion. In a rat model, metformin eye drops applied after glaucoma filtration surgery effectively reduced scarring and improved surgical outcomes by suppressing inflammation and fibrosis around the surgical site.²⁷ Researchers have also developed gel formulations designed to keep metformin on the eye surface longer and release it in a controlled fashion for managing ocular inflammation.²⁸

No metformin eye drop is available for clinical use yet, and human trials for ophthalmic delivery are still years away. But the idea of repurposing a cheap, well-understood molecule as a topical eye treatment is attractive to a field that relies heavily on expensive injectable medications for conditions like wet macular degeneration and diabetic macular edema. If topical metformin eventually proves effective in humans, it could offer a low-cost addition to the eye-care toolkit.

What This Means If You Take Metformin

If you are already on metformin for diabetes, pre-diabetes, or off-label reasons like polycystic ovary syndrome, the overall picture for your eyes is reassuring. The drug does not appear to harm the retina, optic nerve, or any other eye structure at standard doses. In fact, across multiple conditions, it looks like it does measurable good. The main practical takeaway is to keep up with B12 monitoring, because the one plausible route to vision trouble runs through a nutritional deficiency that is entirely preventable with a simple blood test and cheap supplementation.

If you do not have diabetes but are curious about metformin for general health or anti-aging purposes, the eye data is interesting but still observational. Researchers have not yet run the kind of randomized controlled trials needed to prove metformin prevents AMD or glaucoma in otherwise healthy people. The Targeting Aging with Metformin (TAME) trial, a large-scale study designed to test metformin’s effects on aging-related diseases including vision loss, is underway, but results are not expected for several years. Until then, the promise is real but unproven enough that no ophthalmologist would prescribe metformin solely for eye protection.